HARBIN, China, April 20 /PRNewswire-Asia/ -- Renhuang Pharmaceuticals, Inc. (Pink Sheets: RHGP) ("Renhuang" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM"), today announced the appointment of Dr. Changxiong Sun and Mr. Bingchun Wu to its Board of Directors as independent directors effective April 19. Dr. Sun and Mr. Wu will join the Company's Audit Committee, which is chaired by independent director Mr. Sean Shao.
"We extend a warm welcome to Dr. Sun and Mr. Wu as they join our Board as independent directors. The appointments reflect Renhuang's commitment to the highest standards of corporate governance," said Mr. Shaoming Li, Chairman and CEO of Renhuang Pharmaceuticals. "Dr. Sun is a noted expert on management issues, while Mr. Wu brings a lifetime of experience in Chinese medicine to Renhuang's board. We look forward to working with them as we continue to build Renhuang to be the world leader in natural therapeutics for treating depression, melancholy and nerve regulation."
Dr. Sun is a professor of Management Science and Engineering, and a doctoral tutor at the School of Management of Harbin Institute of Technology, one of China's leading universities. Dr. Sun has previously served in senior managerial positions with companies in the private and public sector. He has also served as deputy Secretary General of the Harbin Municipal Government Committee from 2004 to 2005. Dr. Sun holds a PhD from Harbin Institute of Technology.
Mr. Wu has been the Team Leader of Chinese Medicine Research Group at the Heilongjiang Province Chinese Medicine Research Institute. Mr. Wu also served as the Chief Expert of Chinese Medicine at the Heilongjiang Province Science and Technology Department. Prior to that, he was Director of the Chinese Medicine Pharmacology Research Office. Mr. Wu holds a Bachelor's degree in Pharmacy Science from China Medical College and a degree in Finance from Harbin University of Commerce.
ABOUT RENHUANG PHARMACEUTICALS, INC.
Renhuang Pharmaceuticals, Inc. is engaged in the research, development, manufacturing, and distribution of botanical products, bio-pharmaceutical products, and traditional Chinese medicines ("TCM"), in the People's Republic of China. All of the Company's products are produced at its three GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The Company distributes its botanical anti-depression and nerve-regulation products, biopharmaceutical products, and botanical antibiotic and OTC TCMs through its network of over 3,000 distributors and over 70 sales centers across 24 provinces in China.
Safe Harbor Statement
This press release contains certain statements that may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon management's beliefs, assumptions and expectations of the Company's future operations and economic performance, taking into account the information currently available to management. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties, some of which are not currently known that may cause actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition expressed or implied in any forward-looking statements. These forward-looking statements are based on current plans and expectations and are subject to a number of uncertainties including, but not limited to, the Company's ability to achieve its financial guidance, ability to list its shares on a senior stock exchange, ability to manage expansion of its operations effectively, competition in the marketing and sales of its products, and other factors detailed in the Company's annual report on Form 10-K and other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented herein.
For more information, please contact:
Renhuang Pharmaceuticals, Inc.
Ms. Portia Tan, IR Contact
Phone: +86-451-5392-5461
Email: ir@renhuang.com
CCG Investor Relations:
Ms. Lei Huang, Account Manager
Phone: +1-646-833-3417 (New York)
Email: lei.huang@ccgir.com
Web: http://www.ccgirasia.com
Mr. Crocker Coulson, President
Phone: +1-646-213-1915 (New York)
Email: crocker.coulson@ccgir.com
